Asymmetric dimethylarginine and kidney disease - Marker or mediator?

Journal of the American Society of Nephrology

Volumn 16, Issue 8, 2005, Pages 2254-2256

  Vallance, Patrick ^a   Leiper, James ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; C REACTIVE PROTEIN; CITRULLINE; CREATININE; DIMETHYLAMINE; DIMETHYLARGININASE; GUANIDINE DERIVATIVE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE;

AMINO ACID BLOOD LEVEL; DISEASE MARKER; DRUG INHIBITION; EDITORIAL; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN METABOLISM; RISK ASSESSMENT; RISK FACTOR; URINARY EXCRETION;

EID: 28444441237     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005050539     Document Type: Editorial

References (19)

1. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992
2. MacAllister RJ, Whitley GStJ, Vallance P: Effects of guanidine and uremic compounds on nitric oxide pathways. Kidney Int 45: 737-742, 1994
3. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetric dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 358: 2096-2097, 2001
4. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27: 765-769, 2004
5. Fliser D, Kronenberg F, Kielstein JT, Morath C, Bode-Boger SM, Haller H, Ritz E; for the MMKD Study Group: Asymmetric dimethylarginine and progression of chronic renal disease: The Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Neph 16: 2456-2461, 2005
6. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmtrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Neph 16: 2449-2455, 2005
7. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine: A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 98: 1842-1847, 1998
8. Heresztyn T, Worthley MI, Horowitz JD: Determination of 1-arginine and NG,NG- and NG,NG'-dimethyl-L-arginine in plasma by liquid chromatography as AccQ-Flour fluorescent derivatives. J Chromatography 805: 325-329, 2004
9. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C: Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiomyopathy in patients with ESRD. Kidney Int 67: 2330-2337, 2005
10. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Sleiger SL, Newman AB, Siscivick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Eng J Med 352: 2049-2060, 2005
11. Ogawa T, Kinoto M, Sasaoka K: Purification and properties if a new enzyme NG NG dimethylarginine dimethylaminohydrolase from rat kidney. J Biol Chem 264: 10205-10209, 1989
12. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG Whitley GS, Vallance P: Identification of two human dimethyarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343: 209-214, 1999
13. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arteriosder Thromb Vasc Biol 23: 1455-1459, 2003
14. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsika D, Frolich JC, Hoeper MM, Haller H, Fliser D: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetric dimethylarginine in humans. Circulation 109: 172-177, 2004
15. Cayette AJ, Palacino JJ, Horten K, Cohen RA: Chronic inhibition of nitric oxide production accelerates neoimtima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 14: 743-759, 1994
16. Rivas-Cabanero L, Rodriguez-Barbero A, Arevalo M, Lopez-Novoa JM: Effect of NG nitro-L-arginine methyl ester on nephrotoxicity induced by gentamicin in rats. Nephron 71: 203-207, 1995
17. Vallance P, Leiper J, Blocking NO synthesis: How, where and why? Nature Reviews Drug Discovery 2002;1:939-950
18. Bogle RG, MacAllister RJ, Whitley GS, Vallance P: Induction of NG monomethyl-L-arginine uptake: A mechanism for differential inhibition of NO synthases? Am J Physiol 269: C750-C756, 1995
19. Vallance P, Leiper J: Cardiovascular biology of the asymmetric dimethylarginine:DDAH pathway. Arterioscler Thromb Vasc Biol 24:1023-1030, 2004